Status: Ongoing
First registered on:
25/09/2019
Last updated on:
31/10/2019
1. Study identification
EU PAS Register NumberEUPAS31529
Official titleA Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
Study title acronym
Study typeObservational study
Brief description of the studyAn expansion of ongoing post-marketing monitoring of abatacept to include all patients with RA and PsA treated with abatacept with a specific look at select malignancies outcomes.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableBMS IM101-816
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupDepartment of medicine Solna/Clinical epidemiology division
Organisation/affiliationKarolinska Institutet
Details of (Primary) lead investigator
Title Ms
Last name Dominique
First name Alyssa
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Sweden
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed21/06/2019
Start date of data collection01/10/201901/10/2019
Start date of data analysis
Date of interim report, if expected
Date of final study report31/05/2025
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesBristol-Myers Squibb100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Ms
Last name Dominique
First name Alyssa
Address line 1Route 206 and Provinceline Rd
Address line 2
Address line 3
CityPrinceton
Postcode08543
CountryUnited States
Phone number (incl. country code)016092523897
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Ms
Last name Dominique
First name Alyssa
Address line 1Route 206 and Provinceline Rd
Address line 2
Address line 3
CityPrinceton
Postcode08543
CountryUnited States
Phone number (incl. country code)016092523897
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameOrencia
CountryUnited States
Substance INN(s)ABATACEPT
7. Medical conditions to be studied
Medical condition(s)Yes
Rheumatoid arthritis
Psoriatic arthropathy
8. Population under study
Age
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects4000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Disease/case registry
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Primary scope : Disease epidemiology
12. Main objective(s)
What is the main objective of the study?
The objective of this study is to estimate the incidence of pre-specified events of malignancies in abatacept-exposed patients and patients receiving select comparators enrolled in the ARTIS Register.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Incidence of pre-specified malignancies will exclude events reported in the first 180 days of follow-up. Overall cancer IR (95% CI) per 100 p-y and the IR rate will be calculated for abatacept users, anti-TNF users, non-anti-TNF users, and for biologic naive patients. Adjusted HRs will be calculated. Each cohort will be analyzed overall and stratified by indication.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
